NCT03657641View on ClinicalTrials.gov

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

February 27, 2023

Study Completion Date

June 21, 2026

Conditions
Colorectal CancerColorectal Cancer Metastatic
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Regorafenib

Given PO

Trial Locations (3)

33612

Moffitt Cancer Center, Tampa

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT03657641 - Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter